These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 2164938)

  • 41. Interaction of newly synthesized N-cyclopropylmethyl derivatives of (-)-6 beta-acetylthionormorphine with opioid receptors.
    Takayanagi I; Goromaru N; Koike K; Konno F; Mori T; Yoshida M; Kanematsu K
    Gen Pharmacol; 1990; 21(4):541-6. PubMed ID: 2165960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat. Comparison with brain.
    Khawaja XZ; Green IC; Thorpe JR; Titheradge MA
    Biochem J; 1990 Apr; 267(1):233-40. PubMed ID: 1970240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potent morphiceptin analogs: structure activity relationships and morphine-like activities.
    Chang KJ; Wei ET; Killian A; Chang JK
    J Pharmacol Exp Ther; 1983 Nov; 227(2):403-8. PubMed ID: 6313901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
    Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
    Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
    Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
    Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Opioid profiles of Cys2-containing enkephalin analogues.
    Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
    Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of mu-, delta- and kappa-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats.
    Suzuki T; Mori T; Tsuji M; Maeda J; Kishimoto Y; Misawa M; Nagase H
    Eur J Pharmacol; 1997 Apr; 324(1):21-9. PubMed ID: 9137909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid receptor ligands in the neonatal rat spinal cord: binding and in vitro depression of the nociceptive responses.
    James IF; Bettaney J; Perkins MN; Ketchum SB; Dray A
    Br J Pharmacol; 1990 Mar; 99(3):503-8. PubMed ID: 2158845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Morphine tolerance increases mu-noncompetitive delta binding sites.
    Rothman RB; Danks JA; Jacobson AE; Burke TR; Rice KC; Tortella FC; Holaday JW
    Eur J Pharmacol; 1986 May; 124(1-2):113-9. PubMed ID: 3013657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opioid receptor selectivity of peptide models of beta-endorphin.
    Taylor JW; Kaiser ET
    Int J Pept Protein Res; 1989 Jul; 34(1):75-80. PubMed ID: 2551833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of morphine tolerance-dependence and abstinence on mu, delta, and kappa opiate receptors of discrete brain regions and spinal cord of the rat.
    Bhargava HN; Gulati A
    NIDA Res Monogr; 1990; 105():530-1. PubMed ID: 1652091
    [No Abstract]   [Full Text] [Related]  

  • 52. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
    Locke KW; Holtzman SG
    J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterisation of opioid binding sites using selective antagonists.
    Lawrence AJ; Traynor JR
    Prog Clin Biol Res; 1990; 328():121-4. PubMed ID: 1968257
    [No Abstract]   [Full Text] [Related]  

  • 54. Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
    Clark JA; Houghten R; Pasternak GW
    Mol Pharmacol; 1988 Sep; 34(3):308-17. PubMed ID: 2901663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. U50,488H differentially antagonizes the bladder effects of mu agonists at spinal sites.
    Sheldon RJ; Nunan L; Porreca F
    Eur J Pharmacol; 1988 Feb; 146(2-3):229-35. PubMed ID: 2836207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid antagonist properties of the highly delta-receptor-selective BOC-Tyr-Pro-Gly-Phe-Leu-Thr (OtBu) peptide and of its Phe1 and Mel1 analogues.
    Rónai AZ; Magyar A; Orosz G; Borsodi A; Benyhe S; Tóth G; Makó E; Kátay E; Babka E; Medzihradszky K
    Arch Int Pharmacodyn Ther; 1995; 330(3):361-9. PubMed ID: 8836454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    Zernig G; Burke T; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Opioid receptor subtypes involved in the central inhibition of urinary bladder motility.
    Dray A; Metsch R
    Eur J Pharmacol; 1984 Sep; 104(1-2):47-53. PubMed ID: 6094211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse.
    Porreca F; Heyman JS; Mosberg HI; Omnaas JR; Vaught JL
    J Pharmacol Exp Ther; 1987 May; 241(2):393-400. PubMed ID: 3033214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
    Mitrovic I; Napier TC
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.